Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies by Awatef Ben Jemaa et al.
RESEARCH Open Access
Co-expression and impact of prostate specific
membrane antigen and prostate specific
antigen in prostatic pathologies
Awatef Ben Jemaa 1, Yosra Bouraoui 1, Sataa Sallami2, Ahmed Banasr3, Nawfel Ben Rais4, Latifa Ouertani5,
Yassin Nouira2, Ali Horchani2, Ridha Oueslati1*
Abstract
Background: The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA
and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to
elucidate their possible role in tumor progression.
Methods: The study was carried out in 6 normal, 44 benign prostatic hyperplastic and 39 cancerous human
prostates. Immunohistochemical analysis were performed using the monoclonal antibody CD34 to determine the
angiogenic activity, and the monoclonal antibodies 3E6 and ER-PR8 to assess PSMA and PSA expression,
respectively.
Results: In our study we found that in normal prostate tissue, PSMA and PSA were equally expressed (3.7 ± 0.18
and 3.07 ± 0.11). A significant difference in their expression was see in hyperplastic and neoplastic prostates tissues
(16.14 ± 0.17 and 30.72 ± 0.85, respectively) for PSMA and (34.39 ± 0.53 and 17.85 ± 1.21, respectively) for PSA.
Study of prostate tumor profiles showed that the profile (PSA+, PSMA-) expression levels decreased between
normal prostate, benign prostatic tissue and primary prostate cancer. In the other hand, the profile (PSA-, PSMA+)
expression levels increased from normal to prostate tumor tissues. PSMA overexpression was associated with high
intratumoral angiogenesis activity. By contrast, high PSA expression was associated with low angiogenesis activity.
Conclusion: These data suggest that these markers are regulated differentially and the difference in their
expression showed a correlation with malignant transformation. With regard to the duality PSMA-PSA, this implies
the significance of their investigation together in normal and pathologic prostate tissues.
Introduction
The prostate gland is the site of two most pathological
processes among elderly men, benign prostatic hyperpla-
sia (BPH) and prostate cancer (PC) [1]. According to the
zonal origin, prostate cancer arising mainly in the periph-
eral zone (PZ), whereas the transition zone (TZ) is the
exclusive location for the origin of BPH and PC develop-
ing in this latter zone are frequently found incidentally.
There are different biological features between PZ and
TZ of prostate gland [2]. Aberrant prostate growth arises
as a consequence of changes in the balance between cell
proliferation and cell death [3]. This deregulation may
result in production of prostate specific markers such as
the secreted protease prostate-specific antigen (PSA) and
the cell surface prostate-specific membrane antigen
(PSMA) [4]. A transmembrane glycoprotein expressed in
the human prostate parenchyma, from where it was first
cloned and named prostate-specific membrane antigen
(PSMA) [5] has gained increased attention in diagnosis,
monitoring and treatment of PC [6]. PSMA is a metallo-
peptidase belonging to the peptidase family M28 [7] and
has apparent molecular masses of 84-100 kDa [8] with a
unique three-part structure: a short cytoplasmic amino
terminus that interacts with an actin filament, a single
membrane-spanning domain and a large extracellular
domain [9]. Several alternative isoforms have been
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described, including the cytosolic variants PSMA’, PSM-
C, PSM-D [10] and PSMA-E. These variants are thought
to be the consequence of alternative splicing of the
PSMA gene [11]. Concerning prostate tumorigenesis, the
membrane form of PSMA is predominantly expressed.
However, in normal prostate the dominating form of this
protein is the one that appears in the cytoplasm [12,13].
If acting as a transmembrane receptor, PSMA can be
internalized from the plasma membrane and trafficking
through the endocytic system [13]. Although the PSMA
have been noted in a subset of non prostatic tissues
(small intestine, proximal renal tubule), the level of
expression of PSMA in these tissues is less than in pros-
tate tissue [14]. PSMA functions as folate hydrolase and
neuropeptidase [15,16] with expression at low levels in
benign prostatic epithelium and upregulated several fold
in the majority of advanced prostatic malignancies [17].
In these tumors, PSMA immunoexpression has been
shown to correlate with aggressiveness of the PC, with
highest levels expressed in an androgen-deprived state
and metastatic disease [18].
Unlike PSMA, PSA is a 33 kDa glycoprotein of the
kallikrein family of proteases [19]. It is found in normal,
hyperplastic and malignant prostate tissue, and is not
specific biomarker for PC [20]. It is secreted into the
lumen of prostatic duct to liquefy the seminal coagulum
[21]. In invasive adenocarcinomas, disruption of the nor-
mal glandular architecture and loss of the polarity of
prostatic cells appear to allow PSA increased direct leak-
age into peripheral circulation [22]. PSA is the most
widely used serum marker for the diagnosis and follow-
up of PC [23]. Unlike serum PSA, there are drawbacks
to use tissue PSA, like for example, the loss of expres-
sion of tissue PSA associated with advanced disease and
the development of androgen-independent prostate can-
cer (AIPC) [20,24].
Angiogenesis, the establishment of new blood vessels
from preexisting blood, is thought to be required for
process of tumorigenesis and metastasis and may prove
to be a useful prognostic marker for prostate cancer
[25]. A notable finding is that PSMA, an angiogenic
endothelial cell which is like one of several peptidases
that play a role in angiogenesis. PSMA expression was
specifically detected on the neovasculature of many
other prostates not related tumors, suggesting the possi-
bility that PSMA may also functionally contribute to
angiogenesis of primary and metastatic cancers [26,27].
Therefore, it has been suggested that PSMA may be uti-
lized both as a marker and as a therapeutic target [26,6].
In prostate cancer, a significant correlation between
PSMA expression and angiogenesis has been shown
[26,28]. However, the biological role of both angiogenesis
[29] and PSMA expression in PC is still unclear for there
are, indeed, studies in which the presence of these mole-
cules is deprived of any prognostic significance [30].
Interestingly, in vitro and in vivo investigation, it was
revealed that PSA suppresses angiogenesis and, there-
fore, tumor growth and PC invasiveness by activating
the angiostatin-like fragments [31,32].
The present study was undertaken to relate the co-
expression of prostate-associated antigens, PSMA and
PSA, with the degree of vascularization in normal and
pathologic (hyperplasia and cancer) prostate tissues to
elucidate their possible role in tumor progression. On
the basis of the heterogeneity in PSMA and PSA expres-
sion along prostatic tumor progression, we suggested
the presence of various profiles of these prostate-asso-
ciated antigens in each prostatic group (NP, BPH and
PC). This led us to better investigate the association
between the two markers in each prostatic group. The
ultimate question was which, if any, of these factors
could provide additional information regarding the biol-
ogy of prostate tumorigenesis.
Materials and methods
Prostates were obtained from: (i) transurethral resec-
tions from 44 men (aged from 61 to 85 years) diagnosed
clinically and histopathologically with Benign Prostate
Hyperplasia (BPH); (ii) radical prostatectomy from 39
men (aged from 57 to 90 years) diagnosed with prostate
cancer (PC) (dominant Gleason grade ≥7); and (iii) his-
tologically normal prostates (NP) obtained at autopsy
(8-10 hours after death) from 6 men (aged from 21 to
40 years) without histories or reproductive, endocrine or
related diseases.
All pathological, clinical and personal data were anon-
ymized and separated from any personal identifiers.
This study was made with the consent of the patients’
relatives or their family in autopsy cases. All the proce-
dures followed were examined and approved by the
Hospital of La Rabta of Tunis, the Hospital of Charles
Nicolle of Tunis and the Military Hospital of Tunis
(HMPIT) (Tunisia).
The primary antibodies used were: mouse anti-human
PSMA (3E6), mouse anti-human PSA (ER-PR8) and
mouse anti-human CD34 (QBend10) (Dako, Glostrup,
Denmark). CD34 antibody was used to label vessels in
the prostate tissues.
For hematoxylin-eosin staining and immunohisto-
chemistry analysis, tissues were fixed for 24 hours at
room temperature in 0.1 M phosphate-buffered 10% for-
maldehyde, dehydrated and embedded in paraffin. Sec-
tions (3 mm thick) were processed following the
NovoLink™Polymer Detection Systems (Novocastra
Laboratories Ltd, Newcastle, UK) method. Sections were
deparaffinized, rehydrated through graded alcohols and
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washed in de-ionized water. To retrieve antigens, sec-
tions were incubated in citric acid solution (0.1 M, pH
6) for 20 minutes in 98°C using a water bath. Slides
were allowed to cool for another 20 min, followed by
washing in de-ionized water. Endogenous peroxidase
activity was quenched by incubation with Peroxidase
Block for 5 minutes. Each incubation step was carried
out at room temperature and was followed by two
sequential washes (5 min each) in TBS. Sections were
incubated with Protein Block for 5 minutes to prevent
non-specific binding of the first antibody. Thereafter,
the primary antibodies were applied at a dilution of 1/
50 (PSMA) and 1/100 (PSA, CD34) in antibody diluents
(Dako, Glostrup, Denmark) at room temperature for 30
minutes. Afterwards, the sections were incubated with
Post Primary Block for 30 minutes to block non-specific
polymer binding. The sections were incubated with
NovoLink™Polymer for 30 minutes followed by incuba-
tions with 3, 3’-diaminobenzidine (DAB) working solu-
tion for 5 minutes to develop peroxidase activity. Slides
were counterstained with hematoxylin and mounted.
Stainig specificity was checked using negative controls.
Prostatic tissues of each type were incubated in blocking
peptides (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) instead of primary antibodies.
A comparative quantification of immunolabeling in all
tissues types was performed for each of the three anti-
bodies. Of each prostate, six histological sections were
selected at random. In each section, the staining inten-
sity (optical density) per unit surface area was measured
with an automatic image analyzer (Motic Images
Advanced version 3.2, Motic China Group Co., China)
in 5 light microscopic fields per section, using the ×40
objective. Delimitation of surface areas was carried out
manually using the mouse of the image analyzer. For
each positive immunostained section, one negative con-
trol section (the following in a series of consecutive sec-
tions) was also used, and the optic density of this
control section was taken away from that of the stained
section. From the average values obtained (by the auto-
matic image analyzer) for each prostate, the means ±
SEM for each prostatic type (normal prostate, BPH and
PC) were calculated. The number of sections examined
was determined by successive approaches to obtain the
minimum number required to reach the lowest SEM.
The statistical significance between means of the differ-
ent prostate group’s samples was assessed by the Fisher
exact test and the one-way ANOVA test at p≤0.05
(GraphPad PRISMA 5.0 computer program).
Results
We examined human histological specimens (NP, BPH
and PC) by immunohistochemistry to evaluate the rela-
tionship between the co-expression of prostate- associated
antigens (PSMA and PSA) and the degree of vasculariza-
tion (intensity of immunoreaction to CD34).
We didn’t see any immunoreactivity in the negative
controls incubated with blocking peptides (Figure 1A).
Immunorectivity for PSMA appeared in 83% of NP, 86%
of BPH and 97% of PC samples. In NP and BPH sam-
ples, PSMA was exclusively expressed in the cytoplasm
of luminal epithelial cells, whereas we found it only
expressed in the tumor cells of the PC specimens. We
wanted to look at the expression of PSMA in blood vas-
cular, we stained adjacent sections with anti-CD34 and
anti-PSMA antibodies of our samples and we found that
endothelium of both benign and malignant prostate tis-
sues were deprived from PSMA expression (Figure 1C,
G and 1K).
We used Motic advanced software to calculate the
optic density (OD) that correlates with the antigen
expression. We found that the mean of PSMA expres-
sion was significantly increased in benign prostate
glands compared with normal prostate tissue (respec-
tively 16.14 ± 0.17 and 3.7 ± 0.18) (p = 0.008). The
highest level of PSMA expression was found in primary
prostate cancer (30.72 ± 0.85) which significantly dif-
fered from benign (p < 0.0001) and normal prostatic tis-
sue (p < 0.0001) (Figure 2A). Unlike PSMA, PSA
expression was found the highest in hyperplastic epithe-
lial cells (Figure 2B). Scanty immunoreactivity to PSA
was localized in the cytoplasm of epithelial cells in nor-
mal prostate (Figure 1D). Figure 2B showed that the
intensity of immunoreaction to PSA decreased from
BPH samples to prostate adenocarcinoma (34.39 ± 0.53
and 17.85 ± 1.21, respectively) (p < 0.0001). As shown
in this figure, 57% of PC samples positive for PSA have
a similar PSA expression level distribution to NP sam-
ples, whereas 43% have a similar PSA expression level
distribution to BPH samples. PSA staining was present
in 83% of NP, 75% of BPH samples and 74% of PC
samples.
To look at the vasculature in our samples, we immu-
nostained them with anti-CD34 mouse using IHC
method. CD34 consistently showed immunoreactivity in
the plasma membrane of endothelial cells in all pros-
tates specimens (Figure 1E, I and 1M). Measuring the
optical density of CD34 immunostaining, we found that
there is a significant difference in vasculature density
between normal, hyperplasia and tumors in our collec-
tion (Figure 2C). Interestingly, similar to PSMA, CD34
staining was found more abundant in PC specimens
(12.08 ± 0.29), compared with NP and BPH (p <
0.0001). Vessel density was higher in BPH compared to
NP samples (8 ± 0.11 and 2.34 ± 0.15, respectively) (p <
0.0001) (Figure 2C).
To study the relationship between PSMA and PSA
expression and microvessel density in BPH and PC
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samples, we divided BPH and PC samples into 3 sub-
groups. The first group has a CD34 OD values between
2.34 and 8, the second group has a CD34 OD values
between 8 and 12.08 and the third group has a CD34
OD value superior to 12.08 (Figure 2C and Figure 3).
In BPH samples, no difference neither in PSA nor PSMA
expression was found in all 3 subgroups (Figure 3A).
Importantly, depending on the degree of vascularisa-
tion, we found an inverse relation between angiogenesis
and PSA in PC patients. Unlike PSA, the highest intra-
tumoral angiogenesis is accompanied by high PSMA
expression in prostate cancer cells (Figure 3B).
To study the distinct pattern of proteins tumour profiles
produced by prostate epithelial cells we established differ-
ent prostate-associated antigens profiles depending on
positive immunoreactions to PSA and PSMA in NP, BPH
and PC samples. We obtained a negative group for PSA
and/or PSMA in each prostate type. The distribution of
this group was as followed: 2 in NP, 13 in BPH and 11 in
PC patients. Figure 4 showed 4 prostate-associated antigen
profiles expressed differently in NP, BPH and PC patients
as followed: (PSA+, PSMA+), (PSA+, PSMA-), (PSA-,
PSMA-) and (PSA-, PSMA+). For all histological speci-
mens, the profile (PSA+, PSMA+) was the most expressed
in 66% of NP, 70% of patients with BPH and 71% of PC
patients. However, no significance was observed between
the different groups of prostatic specimens according to
the percentage of immunoexpression of the profile (PSA+,
PSMA+). To obtain insights into the relationship between
PSA and PSMA production in the subgroup (PSA+,
PSMA+) along prostatic diseases, we analysed the intensi-
ties of immunoreactions to PSA and to PSMA in NP, BPH
and PC patients for the above profile. As observed in
Figure 5, optical density of PSA increases significantly
from NP to BPH and declines in PC samples in the profile
(PSA+, PSMA+) (p < 0.0001). However, the intensity of
immunoreaction to PSMA increases significantly from NP
to BPH and malignant prostate specimens (p < 0.0001) in
the same profile.
The prostate tumour profile (PSA+, PSMA-) expres-
sion levels decreases from NP to benign prostatic tissue
and primary prostate cancer (50% vs. 15% vs. 2%,
respectively). Inversely, the profile (PSA-, PSMA+)
expression increases from NP to BPH and PC patients
Figure 1 H & E stained slides in NP (B), BPH (F) and PC (J); immunohistochemical localizations of PSMA, PSA and CD34. Negative
control (A). NP showing weak cytoplasmic staining for PSMA (C) and PSA (D) in epithelial cells. CD34 was found at low level in membranous
and cytoplasmic endothelial cells in NP (E) and BPH (I). BPH showing weak membranous staining for PSMA (G) and strong membranous and
cytoplasmic staining for PSA (H) in prostatic epithelial cells. PSMA (K) and CD34 (M) showed strong immunoreactions in infiltrating prostatic
carcinoma. PSA (L) showed weak cytoplasmic immunoreactions of epithelial cells in PC. Scale bars: A-G, I-M, 20 μm; H, 30 μm.
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(50% vs. 53% vs. 90%, respectively). Compared to BPH
patients, the profile (PSA-, PSMA-) was absent in both
NP and PC tissues. This profile was found in 30% of
hyperplastic prostate tissues.
Discussion
A variety of pathological processes lead to the loss of
the normal prostate glandular architecture including
benign prostatic hyperplasia and prostate cancer and its
associated metastases. Aberrant prostate epithelial cells
growth may result in direct production of prostate-asso-
ciated antigens such as the secreted protease prostate-
specific antigen (PSA) and the highly specific membrane
antigen present in their plasma membrane, prostate-
specific membrane antigen (PSMA) [4]. PSMA is an
integral cell surface membrane protein which is highly
specific to prostate gland [14]. Adenocarcinoma of the
prostate, like many epithelial malignancies, initiates in
the terminally differentiated secretory epithelial cells
[33]. In the present study we demonstrated expression
of PSMA within the cells of the prostatic secretory
epithelium in normal, hyperplastic and malignant pros-
tate specimens. We observed an increase of PSMA
expression in prostate cancer. It’ is seems to indicate a
more extensive role of PSMA in prostate cancer. Low
expression in normal tissue would suggest a limited role
of PSMA in normal human prostate and low expression
in benign prostate hyperplasia tissue may suggest a lim-
ited role of this protein in hyperplastic tissue [17,34].
Our finding is consistent with previous reports using
immunohistochemistry and multiplex PCR reactions to
demonstrate the association between PSMA and tumor
progression [17,34,35]. A notable finding in our study
revealed that in NP the expression of PSMA and PSA
seems to be identical. However, PSMA expression in
hyperplastic and neoplastic prostates tissues appears to
be inversed to the PSA expression. Although PSMA is
more expressed in malignant prostate than benign pro-
static hyperplasia, PSA is highly expressed in hyperplas-
tic tissues. This is in part, thought to be due to the
differences observed in several biological features
between peripheral and transition zone of the prostate
gland [2]. Although, the majority of the glandular tissue
in prostate is located in the peripheral zone, the PSA
tissue is secreted at higher levels by benign prostate
epithelium arising exclusively in the transition zone
compared to prostate cancer developing mainly in per-
ipheral zone [36,22]. The majority of our samples diag-
nosed with prostate cancer have a Gleason grade ≥7.
However, regarding to PSA expression we observed a
bi-modal distribution of expression of this marker in
Figure 2 Distribution of tissue PSMA (A), PSA (B) and CD34 (C)
immunostaining intensity (measured as average optical
density) according to normal prostate (NP), benign prostatic
hyperplasia (BPH) and prostatic carcinoma (PC). Average optical
densities were evaluated only in patients showing immunopositivity.
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carcinomatous prostate samples. This is seems to be
related to two mechanisms of growth of this prostate
cancer tissue (data not shown). The study of distinct
pattern of prostate tumor profiles produced by prostate
epithelial cells depending on positive immunoreactions
to PSA and PSMA showed a high immunoexpression of
the profile (PSA+, PSMA+) in all histological prostate
tissues. In this latter profile, PSA and PSMA are more
expressed in BPH compared to NP. The PSMA was
highest in neoplastic cells, whereas PSA was highest in
benign cells in the same profile. For the profile (PSA+,
PSMA-) expression levels decreases between normal
prostate, benign prostatic tissue and primary prostate
cancer. Inversely, the profile (PSA-, PSMA+) expression
increases from NP, BPH to PC patients. Compared to
BPH patients, the profile (PSA-, PSMA-) is absent in
Figure 3 Association between immunostaining intensity of CD34, PSMA and PSA expression among tissue CD34 levels in benign
prostatic hyperplasia (BPH) (A) and prostate cancer (PC) patients (B). Values were expressed as mean ± SEM. Average optical densities
were evaluated only in patients showing immunopositivity. Statistical analysis refers to each antibody separately. Values denoted by different
superscripts are significantly different from each other. Those values sharing the same superscript are not statistically different from each other.
Statistical analysis refers to each antibody separately. Significance was determined at p≤0. 05; 2.34: Mean O.D of CD34 value in NP; 8: Mean O.D
of CD34 value in BPH and 12.08: Mean O.D of CD34 value in PC patients.
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both normal and prostate cancer tissue. These data sug-
gest that these markers are regulated differentially in
their expression and this difference seems to increase
with malignant transformation [34]. The preponderance
of PSMA or PSA expression in each prostatic subgroup
depends on the cellular context. The heterogeneity of
PSMA versus PSA expression under the same sub-group
of prostate-associated profiles is, in part, thought to be
due to the effect of androgen, cytokines, growth factors
receptors, adhesion molecules and many other mem-
brane-generated signals that all share the ability to effi-
ciently regulate PSMA and PSA gene expression
[37,28,38]. Numerous studies indicates that in the
secretory epithelial cells of prostate gland, both PSMA
and PSA transcriptions are androgen-dependent [39,40].
The emergence of androgen-insensitive tumor cells aris-
ing as a consequence of an adaptation to androgen with-
drawal or from pre-existing androgen-independent clone
[33]. According to the androgen levels, PSMA and PSA
are different in several ways. In a previous report Den-
meade SR et al, have identified PSMA as a gene that
was up-regulated in the more aggressive androgen inde-
pendent prostate cancer cell line C4-2B compared to
the androgen-dependent cell line LNCaP [41]. Recently,
in vitro cell-based analysis of PSMA expression was
found that both dihydrotestosterone and 1a, 25-dihy-
droxyvitamin D3 (1, 25-VD) are involved in regulation
of this protein [39]. In human PC, the up-regulation of
PSMA seems to be a late event in tumor progression as
the increase was detected in hormone refractory tumors
compared to normal and benign tissue. Authors have
also indicate that PSMA is important in very advanced
prostate cancer [17,42]. Unlike PSMA, a loss of expres-
sion of tissue PSA has been associated to advanced
prostate cancer and to transition into hormone refrac-
tory tumor growth [32,20]. In addition, several experi-
mental studies have shown that androgen-independent
tumors are more angiogenic than androgen-dependent
tumors [43]. Therefore, our finding suggests a possible
cross talk between PSMA, PSA and intratumoral angio-
genesis and its involvement in tumor growth and metas-
tasis. This relation allowed us to classify the prostate
specimens into groups according to the intensity of
immunoreactions to CD34. In BPH patients, no differ-
ences were found on the intensities of immunoreactions
to PSA or to PSMA regarding the levels of CD34. By
contrast, in PC patients depending on the degree of vas-
cularisation, it was found an inverse relation between
angiogenesis and PSA. Unlike PSA, the highest intratu-
moral angiogenesis is accompanied by high PSMA
expression in prostate cancer cells. This clearly argues
for the view that endothelial cell PSMA expression may
be connected with angiogenesis factors production
which contribute to neoplastic cell proliferation, motility
as well as its contribution to angiogenesis of primary
and metastatic cancers [28]. This view is also in line
with the study of Tsui P et al, reporting that PSMA
expression seems to correlate with vascular endothelial
growth factor (VEGF) which stimulates the directed
growth of endothelial cells toward malignancies through
the process of angiogenesis [44]. The function of PSMA
in late prostate cancer is unknown, but its ability to
remodel extracellular matrix by proteolytic cleavage
might be important. Contrary to PSMA, the results of
an in vitro investigation revealed that PSA, similar to
angiostatin, are implicated in suppressing angiogenesis
and, therefore, also prostate cancer development or
Figure 4 Percentage of prostatic specimens with positive or
negative immunoreactions to PSA and PSMA according to
groups: normal prostate (NP), benign prostatic hyperplasia
(BPH) and prostatic carcinoma (PC). Statistical analysis refers to
each group separately at p≤0.05.
Figure 5 Comparison of the intensity of immunoreactivity
(measured as average optical density ± SEM) for PSA and
PSMA according to groups: normal prostate (NP), benign
prostatic hyperplasia (BPH) and prostatic carcinoma (PC)
among (PSA+, PSMA+) profile. Values denoted by different
superscripts are significantly different from each other. Those values
sharing the same superscript are not statistically different from each
other. Statistical analysis refers to each antibody separately.
Significance was determined at p≤0. 05.
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invasiveness [31]. The vascular suppressive action of
PSA could explain the low proliferation rate of tumor
prostate growth and the low of angiogenesis process in
malignant prostate [32]. In the study of Papadopoulous
et al, it was found that high PSA expression is accompa-
nied by low intratumoral angiogenesis in cancerous
prostate epithelial cells [32]. The association between
high PSA expression and low intratumoral angiogenesis
seems to be consistent with our finding that prostate
cancer expresses significantly less of tissue PSA than
benign prostate tissue. The fundamental agent of angio-
genesis, bFGF, promotes the proliferation and the
migration of prostatic cancer cells by activation of
MAPKs pathway and this effect of bFGF shows to be
modulated by SOCS-3 (Suppressor of cytokine signal-
ling-3) [28,45]. Interestingly, treatment with bFGF sti-
mulates the expression of PSMA in LNCaP (androgen-
dependent) cell line and restores the expression of this
protein in disseminated form of prostate cancer, PC3
and DU145, (androgen-independent cells) [28]. Recently,
Colombatti M et al, reporting for the first time a poten-
tial interaction of PSMA with signaling molecules by
activating the NFkB transcription factor and MAPK
pathways in prostate cancer LNCaP cell line. The
authors suggested a possible cross talk between PSMA,
IL-6 and RANTES chemokine and its implication in cell
proliferation and cell survival in prostate cancer cells
[37].
Conclusion
In conclusion, these data provide further evidence that
PSMA is an important factor in prostate cancer biology.
Moreover, PSMA and PSA seem to be inversely regu-
lated in prostate cells, especially in prostate cancer cells.
Little information exists concerning the role of signaling
pathway in regulating cell apoptosis and survival/angio-
genesis in prostate cancer cells in context to PSMA and
PSA co-expression, formed the basis of our future
study. More understanding of their regulation within
signaling cascade in our prostatic subgroups could be
interesting.
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